<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9522">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05696158</url>
  </required_header>
  <id_info>
    <org_study_id>MHNA-003-001</org_study_id>
    <nct_id>NCT05696158</nct_id>
  </id_info>
  <brief_title>Mahana Tinnitus Pilot</brief_title>
  <official_title>A Prospective, Open-Label Trial of MHNA-003, a Smartphone-Delivered Cognitive Behavioral Therapy (CBT) Treatment, in Adults With Symptoms of Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahana Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahana Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this prospective, open-label, non-significant risk study is to assess&#xD;
      the efficacy and safety of Mahana™ Tinnitus together with care as usual in approximately 250&#xD;
      adults with symptoms of tinnitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following informed consent, all participants will complete a series of screening&#xD;
      questionnaires to determine eligibility for study entry. Eligible participants will be&#xD;
      enrolled, and will receive access to MHNA-003 (Mahana™ Tinnitus). Participants will use&#xD;
      MHNA-003 for 6 weeks, completing assessments at Baseline and Weeks 2, 4, and 6 following&#xD;
      Baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 19, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TFI Score from Baseline to Week 6</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Tinnitus Functional Index (TFI) is a validated, 25-item questionnaire designed to measure the severity and negative impact of tinnitus. Total scores range from 0-100 with higher scores representing higher severity and more negative impact. An improvement of 13 or more points is considered a clinically meaningful change.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>MHNA-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-week digital therapy program designed to reduce the severity of tinnitus symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MHNA-003</intervention_name>
    <description>6-week digital therapy program designed to reduce the severity of tinnitus symptoms</description>
    <arm_group_label>MHNA-003</arm_group_label>
    <other_name>Mahana™ Tinnitus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant scores ≥ 25 on the Tinnitus Functional Index.&#xD;
&#xD;
          -  Participant has experienced symptoms of tinnitus for at least 3 months.&#xD;
&#xD;
          -  Participant is at least 18 years of age at the time of consent.&#xD;
&#xD;
          -  Participant resides in the United States.&#xD;
&#xD;
          -  Participant is able to speak, read, and understand English.&#xD;
&#xD;
          -  Participant has access to an iOS or Android smartphone with the ability to complete&#xD;
             study tasks.&#xD;
&#xD;
          -  Participant is able to commit the time required to complete therapy modules and study&#xD;
             assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant scores ≥2 on item 9 (suicidal thoughts) of the Beck's Depression Index&#xD;
             (BDI).&#xD;
&#xD;
          -  Participant has been hospitalized for psychiatric reasons within 12 months of&#xD;
             screening.&#xD;
&#xD;
          -  Participant is currently enrolled in or plans to enroll in another clinical study that&#xD;
             could impact outcomes of this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mahana Therapeutics</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mahana.com/tinnitus</url>
    <description>Study Home Page</description>
  </link>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 13, 2023</study_first_submitted>
  <study_first_submitted_qc>January 13, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>May 15, 2023</last_update_submitted>
  <last_update_submitted_qc>May 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

